CTIS2024-510612-75-00招募中1 期
Efficacy and safety of once-weekly semaglutide s.c. 2.0 mg as add-on to dose-reduced insulin glargine vs titrated insuline glargine in participants with type 2 diabetes and overweight - NN9535-4801
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 568
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Diagnosed with T2D mellitus =180 days before screening., HbA1c of 7-10% (53-86 mmol/mol) (both inclusive) as assessed by central laboratory on the day of screening., Body mass index (BMI) =25 kg/m2 on the day of screening., Stable daily dose(s) =90 days before screening of any of the following anti-diabetic drugs or combination regimens: -Any metformin formulations =1500 mg or maximum tolerated or effective dose. -Any metformin combination formulation =1500 mg or maximum tolerated or effective dose. The treatment can be with or without SGLT-2 inhibitors., Treated with a once daily basal insulin (e.g. insulin glargine U100 or U300, NPH insulin, insulin detemir, insulin degludec) =40 U/day for =90 days before screening. Short-term bolus insulin treatment for a maximum of 14 days before screening is allowed.
排除标准
- •Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination., Potentially missed diagnosis of Type 1 diabetes (T1D) or latent autoimmune diabetes in adults (LADA) verified by C-peptide <0.26 nmol/L or 260 pmol/L (0.78 ng/mL) or antibodies to glutamic acid decarboxylase (anti-GAD) >5 units/mL, as measured by the central laboratory at screening., Presence or historya of pancreatitis (acute or chronic)., Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of <30 mL/min/1.73 m2 at screening as defined by KDIGO 2012 classification., Any episodes of diabetic ketoacidosis within 90 days before screening., Known hypoglycaemic unawareness as indicated by the investigator according to Clarke’s questionnaire question 8.
研究者
相似试验
进行中（未招募）
1 期
A research study to look into how well semaglutide, together with insulin glargine, compares to a higher dose of insulin glargine alone in people with type 2 diabetesDiabetes Mellitus, type 2MedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2021-004392-13-ESovo Nordisk A/S568
进行中（未招募）
1 期
A research study to look into how well semaglutide, together with insulin glargine, compares to a higher dose of insulin glargine alone in people with type 2 diabetesDiabetes Mellitus, type 2MedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2021-004392-13-SKovo Nordisk A/S568
进行中（未招募）
1 期
A research study to look into how well semaglutide, together with insulin glargine, compares to a higher dose of insulin glargine alone in people with type 2 diabetesDiabetes Mellitus, type 2MedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2021-004392-13-GRovo Nordisk A/S568
进行中（未招募）
1 期
A research study to look into how well semaglutide, together with insulin glargine, compares to a higher dose of insulin glargine alone in people with type 2 diabetesEUCTR2021-004392-13-PTovo Nordisk A/S568
进行中（未招募）
1 期
Efficacy and safety of semaglutide once-weekly versus placebo as add on to SGLT-2i in subjects with type 2 diabetes mellitus.MedDRA version: 19.0 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus System Organ Class: 100000004861Diabetes Mellitus, Type 2EUCTR2016-000904-27-NOovo Nordisk A/S302